(Reuters) -Retail investors are dialing back their risky bets after the longest bullish streak in recent years, J.P. Morgan analysts wrote in a note, marking a shift in sentiment that could sap momentum in high-flying U.S. stocks. The brokerage's readout from Friday showed a drop in bullish options bets, with call volumes slipping compared to puts, after roughly 140 days...

Overview * Company advancing rese-cel clinical trials with promising data for autoimmune diseases * Cabaletta expects cash reserves to fund operations into the second half of 2026 Outlook * Cabaletta plans BLA submission for rese-cel in 2027 * Company expects FDA alignment on cohort designs by end of 2025 * Cabaletta anticipates enrollment in registrational cohorts in 2026 Result Drivers...

Acquisition deepens Revvity Signals’ presence in research informatics while furthering its ongoing expansion into development and manufacturing solutions WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. ( RVTY ) , today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end...

Overview * ADC Therapeutics ( ADCT ) Q3 net income and income from operations beat analyst expectations * Net product revenues for Q3 2025 declined due to lower sales volume * Completed $60 mln PIPE financing to expand ZYNLONTA and strengthen balance sheet Outlook * ADC Therapeutics ( ADCT ) expects LOTIS-7 data by end of 2025 * Company anticipates...